Nonsurgical Management of CTEPH: Medical

Inoperable CTEPH: Defining the Role of Medical Treatment Alison Witkin, MD

The Hematology of CTEPH: Perioperative Considerations Richard Channick, MD

Post-PTE Anticoagulation, Warfarin vs. DOACs: End of the INR? Ivan Robbins, MD

Life After PTE: Residual PH Assessment and Mechanical VTE Risk Mitigation Anjali Vaidya, MD, FACC, FASE, FACP

Balloon Pulmonary Angioplasty: The New Frontier

The Great Debate: Distal CTEPH – Getting to the Root of the Problem: PTE or BPA? Michael Madani, MD, FACS and Robert Frantz, MD

Technical Considerations and Challenges in BPA Riyaz Bashir, MD

BPA: How Much BPA Is Enough? Targets, Goals, and Limitations Richard Krasuski, MD

BPA After PTE: Whether to Consider, When to Do It Ken Rosenfield, MD

Case Presentations

Medical Management in a Non-PTE Candidate Michael Cuttica, MD

Handling Vessel Injury and Hemoptysis After a BPA David Poch, MD

BPA Combined with Medical Management in Inoperable CTEPH Vladimir Lakhter, DO

By the end of the session the participant will be able to:

• Discuss an updated understanding of the pathophysiology of CTEPH
• Describe the latest diagnostic and evaluative approaches to patients with suspected chronic thromboembolic disease and apply that information to a patient case
• Explain the role of balloon pulmonary angioplasty in the management of inoperable CTEPH and apply that information to a patient case
• Define the role of medical therapy in selected patient groups with CTEPH and apply that information to a patient case

ACCME Activity #201861290

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

• Sonja Bartolome, MD: Consultant – Janssen
• Riyaz Bashir, MD: Equity Holder – Thrombolex, Inc.
• Richard N. Channick, MD: Speaker – Actelion, Bayer; Advisor – Actelion, Bayer, Gossamer, Third Pole, Aria CV, Acceleron
• Michael Cuttica, MD: Consultant, Speaker Bureau, Advisory Board, PI – Bayer; Speaker Bureau, Advisory Board, Consultant – United Therapeutics, Janssen
• Paul Forfia, MD: Consultant – Bayer, Janssen, United Therapeutics
• Robert P. Frantz, MD, FACC: Grant application review board, with compensation to institution – Bayer; Paid Consulting: Janssen, Liquidia; Consulting, with payment to institution: Acceleron, Gossamer Bio; Presentations, with payment to institution: United Therapeutics; Advisory Board – Janssen; Steering Committee – Janssen
• Richard A. Krasuski, MD: Paid Consultant – Actelion/Janssen, Gore Medical; Research Funding – Actelion/Janssen; Investigator – Edwards Lifesciences, Corvia, CryoLife, and Medtronic; Travel Grants – CryoLife, Medtronic
• Michael M. Madani, MD: Paid Consultant – Actelion/Janssen, Bayer, Merck, Wexler Surgical

• Vallerie McLaughlin, MD: Grant support – Acceleron, Janssen, Sonovie, United Therapeutics; Scientific Consulting – Acceleron, Aerovate, Altavant, Bayer, Caremark, Civi Biopharma, Corvista, Gossamer Bio, Janssen, Merck, United Therapeutics
• David Poch, MD: Investigator – Janssen, United Therapeutics, Phase Bio, Acceleron
• Ivan Robbins, MD: Advisory Board, PI – Bayer; PI – Complexa, Inc.; PI – Altavant Sciences; Advisory Board, PI – Acceleron Pharma

• Kenneth Rosenfield, MD: Consultant/Scientific Advisory Board: Althea Medical, Angiodynamics, Boston Scientific, Contego, InspireMD, Magneto, Neptune Medical, Philips, Summa Therapeutics, Surmodics, Thrombolex, Terumo, Truvic; Institutional Grants: Boston Scientific; Shareholder: Accolade, Access Vascular, Althea Medical, Contego, Cruzar Systems, Embolitech, Endospan, InspireMG, JanaCare, Magneto, Orchestra, PQ Bypass, Prosomnus, Shockwave, Summa Therapeutics, Thrombolex, Truvic, Valcare
• Anjali Vaidya, MD: Consultant, Speaker Bureau: Bayer
• Alison Witkin, MD: Advisory Board, United Therapeutics

The following individuals have no conflicts of interest to disclose:

• Vlad Lakhter DO, SVM
• Charles Turck, PharmD, BCPS, BCCCP, President, ScientiaCME (Reviewer)

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

*Required to view Printable PDF Version